NCT04685486

Brief Summary

This study is a randomized proof-of-concept study to assess the efficacy of Virtual Reality (VR) vs standard of care in 50 adult patients in the New York Presbyterian Burn Unit. The participants who are randomized to receive the virtual reality intervention will also receive opioids, which is the standard of care and is known to be effective. Participants will be randomly assigned to two groups. The first group will receive VR during their painful procedure (e.g., wound dressing changes, physical therapy etc.) in addition to the standard of care. The other group will receive standard of care (and no VR).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable pain

Timeline
Completed

Started Jun 2018

Longer than P75 for not_applicable pain

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2018

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

December 22, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 28, 2020

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

August 3, 2025

Status Verified

July 1, 2025

Enrollment Period

7.8 years

First QC Date

December 22, 2020

Last Update Submit

July 30, 2025

Conditions

Keywords

Virtual RealityPain ManagementAnxietyDepression

Outcome Measures

Primary Outcomes (2)

  • Change in Pain

    Initial determination of the clinical efficacy of VR in reducing the total pain (determined by the subjective standard 0-10 pain scale) where 0 = no pain and 10 = worst pain.

    Peri-procedural: 30 minutes before to two hours after the painful event.

  • Change in narcotic dose

    Dose of narcotics needed peri-procedure

    Peri-procedural: 30 minutes before to two hours after the painful event.

Secondary Outcomes (4)

  • Change in narcotic dose

    Day 1 of hospitalization to last day of hospitalization (approximately 15 days)

  • Change in anxiolytics dose

    Day 1 of hospitalization to last day of hospitalization (approximately 15 days)

  • Change in Anxiety Symptoms

    Peri-procedural: 30 minutes before to two hours after the painful event.

  • Change in Depressive Symptoms

    Peri-procedural: 30 minutes before to two hours after the painful event.

Study Arms (2)

Virtual Reality

EXPERIMENTAL

Virtual reality-enhanced distraction using a portable head mounted display during panful events (such as wound dressing changes or physical therapy sessions) in addition to standard of care.

Other: Virtual Reality

Treatment as Usual

NO INTERVENTION

Standard of care during painful event (such as wound dressing changes or physical therapy sessions).

Interventions

Immersive and interactive game played through a portable head-mounted display as a distraction mechanism

Virtual Reality

Eligibility Criteria

Age8 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • years and older
  • Patients with a burn injury and is in the Burn Unit at New York Presbyterian
  • Awake, alert, ambulatory
  • The burn comprises less than 15% total body surface area (TBSA)
  • The patient does not require conscious sedation such as ketamine for staple removal or wound dressing changes
  • The patient is able to give informed consent

You may not qualify if:

  • Diagnosis of a cognitive disorder, psychotic disorder or bipolar I as determined by self-report from previous diagnosis
  • Current opioid abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Weill Cornell Medicine

New York, New York, 10065, United States

RECRUITING

MeSH Terms

Conditions

PainAgnosiaAnxiety DisordersDepression

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System DiseasesMental DisordersBehavioral SymptomsBehavior

Study Officials

  • JoAnn Difede, PhD

    Weill Medical College of Cornell University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Olivia Baryluk, BS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 22, 2020

First Posted

December 28, 2020

Study Start

June 1, 2018

Primary Completion

April 1, 2026

Study Completion

May 1, 2026

Last Updated

August 3, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations